Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
HIKAL
Mr. Sameer Jai Hiremath · Navi Mumbai, India
₹216.99
▼-1.98%Hikal is trading near the lower end of its 52‑week range as earnings miss weighs, but strong top‑line growth and niche specialty drug franchise keep the upside potential alive.
Exchange
NSI
Currency
INR
Day range
₹216.01 – ₹222.88
52-week range
₹146.25 – ₹330.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis68% confidence
The stock appears undervalued relative to its growth trajectory, trading well below its 52‑week high and offering a margin of safety versus intrinsic estimates.
34.2% below the 1-year high · trend down
Hedge-fund memo
Today
Shares slipped 1.98% to INR 216.99, staying within the day’s range and testing support near INR 216.
This week
The stock has been range‑bound, hovering between INR 210‑225, as investors digest a negative EPS surprise.
This month
Over the past month Hikal has rallied from the low‑150s to the current level, reflecting improving revenue growth and a bullish analyst consensus.
Bull thesis
Bear thesis
News & sentiment
Neutral
11 headlines · 9 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Earnings history unavailable for this symbol.
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| HIKAL | 26.76B | — | — | 13.16% | 37.30% |
| INDOCO | 19.97B | 637.32 | — | 1.39% | 6.80% |
| FDC | 66.34B | 23.58 | 11.81% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 498sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Raw material price volatility
Mitigation: Long‑term supply contracts and hedging where feasible.
Regulatory setbacks on pipeline drugs
Mitigation: Diversify product mix across geographies and therapeutic areas.
Business intelligence
Competitive moat
A well‑established API platform and long‑term contracts with multinational pharma firms provide a defensible niche moat.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Q3 earnings with expected EBIT margin improvement
Regulatory approval of a new specialty drug in US/EU markets
Thesis builder
Bull case
Sustained double‑digit revenue growth and a niche specialty API franchise will lift margins and drive earnings recovery.
Base case
Current valuation reflects a discount to peers given profit lag, but upside remains if the company converts top‑line growth into positive EPS.
Bear case
If cost inflation persists and the company fails to achieve operating leverage, profitability could remain negative, pressuring the stock further.
Time horizon
12‑18 months
Est. CAGR
15%‑25% annual revenue growth over the next 3‑5 years
Entry (qual.)
Buy on pullbacks toward INR 200‑210, where valuation offers a margin of safety.
Exit (qual.)
Target INR 280‑300 if EPS turns positive and margin expands, or exit if price breaches the 52‑week low with deteriorating fundamentals.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how HIKAL fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain HIKAL for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
Accumulate on dips; the upside from earnings turnaround outweighs short‑term profit warnings.
Free Press Journal·7h ago·sustainability excellence
scanx.trade·10h ago
InvestyWise·12h ago
Manufacturing Today India·1d ago·sustainability award
MarketsMojo·1d ago·mixed market signals
MarketsMojo·2d ago·technical indicators
Prop News Time·5d ago·new cGMP pilot plant
Indiatimes·6d ago·advanced cGMP pilot plant
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
| 15.73% |
| 18.90% |
| AARTIDRUGS | 37.68B | 19.34 | 13.36% | 10.90% | 6.40% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹216.01
Resistance (day/52w high)
₹222.88
Volume
1,23,310
Trend
down
RSI (14)
42
MACD
bearish
MA cross
golden
50-day MA
₹211.51
200-day MA
₹207.52
vs 200-DMA
4.6%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Overall conviction 68%